SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Syndax Pharmaceuticals Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$13.09+0.19 (+1.47%)

Close on Oct 19, 2026

Market cap: $1.16B
P/E (TTM): –
Dividend yield: –

Syndax Pharmaceuticals Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	172	24	0	0	140	1.52	1.52	1.52	2.11	1.22	0.63	–
Research & Development	259	242	163	118	88	50	43	60	48	32	9.55	10
Selling, General & Admin	180	121	67	33	25	–	–	–	–	–	–	–
General & Administrative	–	–	–	33	25	23	16	17	16	13	12	11
Advertising Expenses	14	7.30	6.10	1.50	–	–	–	–	–	–	–	–
Operating Expenses	445	363	230	152	113	73	59	77	64	45	21	21
Operating Income	-273	-340	-230	-152	26	-71	-58	-76	-62	-44	-21	-21
Interest Expense	0.01	0.00	0.21	3.14	1.90	2.36	–	–	–	–	–	–
Interest & Investment Income	23	26	21	5.87	0.40	0.84	1.57	1.94	–	–	–	–
Other Non-Operating Income	-12	21	21	2.42	-1.29	-1.74	1.49	1.92	1.15	-0.71	-3.61	1.50
Income Tax Expense	0.43	–	–	–	0	0	0	0	0	0	0	–
Net Income incl. Noncontrolling Interests	-285	-319	-209	-149	25	-73	-56	-74	-61	-44	–	–
Net Income	-285	-319	-209	-149	25	-73	-56	-74	-61	-44	-24	-20
Net Income to Common	-285	-319	-209	-149	25	-77	-56	-74	-61	-47	-104	-26
EPS (Basic)(per share)	-3.29	-3.72	-2.98	-2.46	0.48	-1.87	-1.84	-2.92	-2.90	-3.22	-1,519.27	-453.02
EPS (Diluted)(per share)	-3.29	-3.72	-2.98	-2.46	0.46	-1.87	-1.84	-2.92	-2.90	-3.22	-1,519.27	-453.02
Shares Outstanding (Basic, Weighted)(shares)	87	86	70	61	52	41	30	25	21	15	0.07	0.06
Shares Outstanding (Diluted, Weighted)(shares)	87	86	70	61	54	41	30	25	21	15	0.07	0.06

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -77.0%
Net margin: -87.5%
Return on equity, FY2025: -161.8%

Financial strength

Current ratio: 6.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 337.6%

Valuation

P/E ratio: –
Price to sales: 4.62
Price to book: 77.15
Dividend yield: –